Table 3.
The Baseline Data for the High RHR Group and Low RHR Group After PSM
| Variable | RHR<0.473(n=145) | RHR≥0.473(n=145) | P-value |
|---|---|---|---|
| Demographic | |||
| Age | 72.1 (66.1, 80.6) | 74.8 (63.8, 83.5) | 0.513 |
| Male | 58 (40.0) | 64 (44.1) | 0.475 |
| Ethnicity | |||
| White | 104 (71.7) | 102 (70.3) | 0.888 |
| Black | 19 (13.1) | 18 (12.4) | |
| Others | 22 (15.2) | 25 (17.2) | |
| Vital signs | |||
| HR (beats/min) | 106.0 (93.0, 125.0) | 108.0 (91.0, 121.0) | 0.950 |
| RR (beats/min) | 30.0 (27.0, 35.0) | 30.0 (26.0, 35.0) | 0.576 |
| SBP (mmHg) | 148.0 (131.0, 163.0) | 148.0 (133.0, 164.0) | 0.861 |
| DBP (mmHg) | 94.0 (81.0, 107.0) | 90.0 (79.0, 105.0) | 0.224 |
| MAP (mmHg) | 103.0 (94.0, 122.0) | 103.0 (92.0, 117.8) | 0.249 |
| SpO2 (%) | 100.0 (99.0, 100.0) | 100.0 (99.0, 100.0) | 0.904 |
| Laboratory | |||
| WBC (K/uL) | 11.9 (8.7, 15.3) | 10.9 (7.9, 15.6) | 0.500 |
| PLT (K/uL) | 219.0 (174.0, 264.0) | 213.0 (151.0, 271.0) | 0.302 |
| Potassium (mEq/L) | 4.5 (4.2, 5.1) | 4.5 (4.1, 5.0) | 0.236 |
| Sodium (mEq/L) | 141.0 (138.0, 143.0) | 140.0 (137.0, 144.0) | 0.571 |
| Glucose (mg/dL) | 150.0 (126.0, 197.0) | 152.0 (122.0, 191.0) | 0.688 |
| Cr (mg/dL) | 1.1 (0.8, 1.5) | 1.1 (0.8, 1.8) | 0.457 |
| PH | 7.40 (7.35, 7.45) | 7.39 (7.35, 7.44) | 0.453 |
| PaCO2 (mmHg) | 56.0 (46.0, 71.0) | 56.0 (46.0, 68.0) | 0.890 |
| Anion gap (mEq/L) | 15.0 (13.0, 18.0) | 15.0 (13.0, 18.0) | 0.561 |
| Bicarbonate (mEq/L) | 27.0 (23.0, 32.0) | 27.0 (23.0, 30.0) | 0.609 |
| Comorbidities | |||
| Hypertension | 40 (27.6) | 37 (25.5) | 0.690 |
| Diabetes | 18 (12.4) | 19 (13.1) | 0.860 |
| Asthma | 8 (5.5) | 8 (5.5) | 1.000 |
| Pulmonary embolism | 6 (4.1) | 4 (2.8) | 0.520 |
| Anemia | 28 (19.3) | 23 (15.9) | 0.441 |
| Hematological malignancies | 1 (0.7) | 3 (2.1) | 0.615 |
| Connective tissue diseases | 5 (3.5) | 5 (3.5) | 1.000 |
| Peripheral vascular diseases | 11 (7.6) | 9 (6.2) | 0.643 |
| Myocardial infarction | 18 (12.4) | 19 (13.1) | 0.860 |
| Liver disease | 2 (1.4) | 3 (2.1) | 1.000 |
| Chronic kidney disease | 15 (10.3) | 14 (9.7) | 0.845 |
| Malignant tumors | 10 (6.9) | 10 (6.9) | 1.000 |
| Sepsis | 29 (20.0) | 34 (23.5) | 0.476 |
| Prescriptions* | |||
| Corticosteroid | 3 (2.1) | 4 (2.8) | 1.000 |
| Bronchodilators | 90 (62.1) | 98 (67.6) | 0.325 |
| Vasopressors | 3 (2.1) | 4 (2.8) | 1.000 |
| Intravenous fluids | 97 (66.9) | 103 (71.0) | 0.446 |
| Blood transfusions | 5 (3.5) | 4 (2.8) | 1.000 |
| Mechanical ventilation | |||
| Invasive | 42 (29.0) | 46 (31.7) | 0.609 |
| Non-invasive | 39 (26.9) | 36 (24.8) | 0.687 |
| Score | |||
| SOFA | 4.0 (2.0, 6.0) | 4.0 (3.0, 7.0) | 0.321 |
| SAPSII | 36.0 (28.0, 44.0) | 36.0 (28.0, 46.0) | 0.643 |
| ICU stay (day) | 3.0 (1.7, 6.2) | 3.2 (1.9, 6.0) | 0.688 |
| 28-day mortality (%) | 20 (13.8) | 43 (29.7) | 0.001 |
Notes: *All prescriptions were issued within 24 hours of ICU admission for patients. A p-value less than 0.05 is considered statistically significant.
Abbreviations: HR, Heart Rate; RR, Respiratory Rate; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MAP, Mean Arterial Pressure; WBC, White Blood Cell; PLT, Platelet; Cr, Creatinine; SOFA, Sequential Organ Failure Assessment; SAPSII, Simplified Acute Physiology ScoreII.